A current perspective of pituitary adenoma MRI characteristics: a review

References

• Lundin P, Nyman R, Burman P, et al. MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiology. 1992;34:43–51.
   PubMed Web of Science ®Google Scholar
• Lundin P, Pedersen F. Volume of pituitary macroadenomas - assessment by MRI. J Comput Assist Tomogr. 1992;16(4):519–528.
   PubMed Web of Science ®Google Scholar
• Lundin P, Bergstrom K, Nyman R, et al. Macroprolactinomas: serial MR imaging in long-term bromocriptine therapy. Am J Neuroradiol. 1992;13(5):1279–1291.
   PubMed Web of Science ®Google Scholar
• Lundin P, Engström BE, Karlsson F, et al. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. Am J Neuroradiol. 1997;18(4):765–772.
   PubMed Web of Science ®Google Scholar
• Marro B, Zouaoui A, Sahel M, et al. MRI of pituitary adenomas in acromegaly. Neuroradiology. 1997;39(6):394–399.
   PubMed Web of Science ®Google Scholar
• Hagiwara A, Inoue Y, Wakasa K, et al., Comparison of growth hormone–producing and non–growth hormone–producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology. 2003;228(2): 533–538.
   PubMed Web of Science ®Google Scholar
• Bonneville J-F, Bonneville F, Cattin F. Magnetic resonance imaging of pituitary adenomas. Eur Radiol. 2005;15:543–548.
   PubMed Web of Science ®Google Scholar
• Bonneville J-F, Bonneville F, Cattin F, et al. MRI of the pituitary gland. Switzerland: Springer; 2016.
   Google Scholar
• Bashari WA, Senanayake R, Fernandez-Pombo A, et al. Modern imaging of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101278.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S. Imaging of pituitary pathology. Handb Clin Neurol. 2014;124:151–166.
   PubMedGoogle Scholar
• Pinker K, Ba-Ssalamah A, Wolfsberger S, et al. The value of high-field MRI (3 T) in the assessment of sellar lesions. Eur J Radiol. 2005;54(3):327–334.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951.
   PubMed Web of Science ®Google Scholar
• Melmed S. Melmed S new therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016;12(2):90–98.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243–248.
   PubMed Web of Science ®Google Scholar
• Bourdelot A, Coste J, Hazebroucq V, et al. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol. 2004;150(6):763–771.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21(4):667–678.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Biller BM, Freda PU, et al. A pituitary society update to acromegaly management guidelines. Pituitary. 2021;24(1):1–13.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847–875.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–288.
   PubMed Web of Science ®Google Scholar
• Varlamov EV, Hinojosa-Amaya JM, Fleseriu M. Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. Pituitary. 2020;23(1):16–26.
   PubMed Web of Science ®Google Scholar
• Esposito D, Olsson DS, Ragnarsson O, et al. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary. 2019;22(4):422–434.
   PubMed Web of Science ®Google Scholar
• Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894–904.
   PubMed Web of Science ®Google Scholar
• Vasilev V, Rostomyan L, Daly AF, et al. Management of endocrine disease: pituitary ‘incidentaloma’: neuroradiological assessment and differential diagnosis. Eur J Endocrinol. 2016;175(4):R171–R184.
   PubMed Web of Science ®Google Scholar
• Raverot G, Burman P, McCormack A, et al. European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1–G24.
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege. Belgium J Clin Endocrinol Metab. 2006;91: 4769–4775.
   PubMed Web of Science ®Google Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377–382.
   PubMed Web of Science ®Google Scholar
• Raappana A, Koivukangas J, Ebeling T, et al. Incidence of pituitary adenomas in Northern Finland in 1990–2007. J Clin Endocrinol Metab. 2010;95:4268–4275.
   PubMed Web of Science ®Google Scholar
• Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16:545–553.
   PubMed Web of Science ®Google Scholar
• Tjörnstrand A, Gunnarsson K, Evert M, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol. 2014;171(4):519–526.
   PubMed Web of Science ®Google Scholar
• Agustsson TT, Baldvinsdottir T, Jonasson JG, et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol. 2015;173(5):655–664.
   PubMed Web of Science ®Google Scholar
• Oh JS, Kim HJ, Hann HJ, et al. Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study. Pituitary. 2021;24(1):38–47.
   PubMed Web of Science ®Google Scholar
• Choi SH, Kwon BJ, Na DG, et al. Pituitary adenoma, craniopharyngioma, and Rathke cleft cyst involving both intrasellar and suprasellar regions: differentiation using MRI. Clin Radiol. 2007;62(5):453–462.
   PubMed Web of Science ®Google Scholar
• Bakhtiar Y, Hanaya R, Tokimura H, et al. Geometric survey on magnetic resonance imaging of growth hormone producing pituitary adenoma. Pituitary. 2014;17(2):142–149.
   PubMed Web of Science ®Google Scholar
• Gruppetta M, Vassallo J. Epidemiology and radiological geometric assessment of pituitary macroadenomas: population‐based study. Clin Endocrinol (Oxf). 2016;85(2):223–231.
   PubMed Web of Science ®Google Scholar
• Dogansen SC, Yalin GY, Tanrikulu S, et al., Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary. 2018;21(4): 347.
   PubMed Web of Science ®Google Scholar
• Gruppetta M, Formosa R, Falzon S, et al. Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas. Pituitary. 2017;20(3):358–371.
   PubMed Web of Science ®Google Scholar
• Chacko G, Chacko AG, Kovacs K, et al. The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary. 2010;13(4):337–344.
   PubMed Web of Science ®Google Scholar
• Fougner SL, Casar-Borota O, Heck A, et al. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf). 2012;76(1):96–102.
   PubMed Web of Science ®Google Scholar
• Larkin S, Reddy R, Karavitaki N, et al. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol. 2013;168(4):491–499.
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol. 2014;52(3):R223–R240.
   PubMed Web of Science ®Google Scholar
• Pierallini A, Caramia F, Falcone C, et al. Pituitary macroadenomas: preoperative evaluation of consistency with diffusion-weighted MR imaging—initial experience. Radiology. 2006;239(1):223–231.
   PubMed Web of Science ®Google Scholar
• Yiping L, Ji X, Daoying G, et al. Prediction of the consistency of pituitary adenoma: a comparative study on diffusion-weighted imaging and pathological results. J Neuroradiol. 2016;43(3):186–194.
   PubMed Web of Science ®Google Scholar
• Zeynalova A, Kocak B, Durmaz ES, et al. Preoperative evaluation of tumour consistency in pituitary macroadenomas: a machine learning-based histogram analysis on conventional T2-weighted MRI. Neuroradiology. 2019;61(7):767–774.
   PubMed Web of Science ®Google Scholar
• Puig-Domingo M, Resmini E, Gomez-Anson B, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010;95(11):4973–4978.
   PubMed Web of Science ®Google Scholar
• Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2‐weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2012;77(1):72–78.
   PubMed Web of Science ®Google Scholar
• Potorac I, Petrossians P, Daly AF, et al., Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer. 2015;22(2): 169–177.
   PubMed Web of Science ®Google Scholar
• Swanson AA, Erickson D, Donegan DM, et al. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary. 2021;24(2):192–206.
   PubMed Web of Science ®Google Scholar
• Heck A, Emblem KE, Casar-Borota O, et al. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. 2016;52(2):333–343.
   PubMed Web of Science ®Google Scholar
• Heck A, Emblem KE, Casar-Borota O, et al. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine. 2016;53(1):327–330.
   PubMed Web of Science ®Google Scholar
• Potorac I, Petrossians P, Daly A, et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer. 2016;23(11):871–881.
   PubMed Web of Science ®Google Scholar
• Bonneville F, Rivière LD, Petersenn S, et al. MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post hoc analysis. Eur J Endocrinol. 2019;180(3):155–164.
   Web of Science ®Google Scholar
• Coopmans EC, Schneiders JJ, El-Sayed N, et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182(6):595–605.
   PubMedGoogle Scholar
• Shen M, Zhang Q, Liu W, et al. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology. 2016;58(11):1057–1065.
   PubMed Web of Science ®Google Scholar
• Kocak B, Durmaz ES, Kadioglu P, et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019;29(6):2731–2739.
   PubMed Web of Science ®Google Scholar
• Galm BP, Buckless C, Swearingen B, et al. MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands. Pituitary. 2020;23(3):212–222.
   PubMed Web of Science ®Google Scholar
• Park YW, Kang Y, Ahn SS, et al. Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary. 2020;23(6):691–700.
   PubMed Web of Science ®Google Scholar
• Kreutz J, Vroonen L, Cattin F, et al. Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology. 2015;57(7):679–684.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Nakayama T, Ohata K, et al. Computed tomography and magnetic resonance imaging appearance of prolactinoma with spheroid-type amyloid deposition. J Comput Assist Tomogr. 2011;35(2):313–315.
   PubMed Web of Science ®Google Scholar
• Levine SN, Ishaq S, Nanda A, et al. Occurence of extensive amyloid deposits in a prolactin secreting pituitary macroadenoma: a radiologic-pathologic correlation. Ann Diagn Pathol. 2013;7:361–366.
   Google Scholar
• Burlacu MC, Maiter D, Duprez T, et al. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine. 2019;63(2):323–331.
   PubMed Web of Science ®Google Scholar
• Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol. 2009;4:97–126.
   PubMed Web of Science ®Google Scholar
• Mete O, Asa SL. Asa SL clinicopathological correlations in pituitary adenomas. Brain Pathol. 2012;22(4):443–453.
   PubMed Web of Science ®Google Scholar
• Saeger W, Honegger J, Theodoropoulou M, et al. Clinical impact of the current WHO classification of pituitary adenomas. Endocr Pathol. 2016;27(2):104–114.
   PubMed Web of Science ®Google Scholar
• Liu W, Zahr RS, McCartney S, et al. Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary. 2018;21(5):454–462.
   PubMed Web of Science ®Google Scholar
• Kurosaki M, Kambe A, Watanabe T, et al. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas. Neurol Res. 2015;37(4):341–346.
   PubMed Web of Science ®Google Scholar
• Faje A, Chunharojrith P, Nency J, et al. Dopamine agonists can reduce cystic prolactinomas. J Clin Endocrinol Metab. 2016;101(10):3709–3715.
   PubMed Web of Science ®Google Scholar
• Syro LV, Rotondo F, Cusimano MD, et al. Current status on histological classification in Cushing’s disease. Pituitary. 2015;18(2):217–224.
   PubMed Web of Science ®Google Scholar
• Zada G, Lin N, Laws JER. Patterns of extrasellar extension in growth hormone-secreting and nonfunctional pituitary macroadenomas. Neurosurg Focus. 2010;29(4):E4.
   PubMed Web of Science ®Google Scholar
• Bette S, Butenschön VM, Diestler B, et al. MRI criteria of subtypes of adenomas and epithelial cysts of the pituitary gland. Neurosurg Rev. 2020;43(1):265–272.
   PubMed Web of Science ®Google Scholar
• Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993;33(4):610–617.
   PubMed Web of Science ®Google Scholar
• Cottier JP, Destrieux C, Brunereau L, et al. Cavernous sinus invasion by pituitary adenoma: MR imaging 1. Radiology. 2000;215(2):463–469.
   PubMed Web of Science ®Google Scholar
• Micko AS, Wöhrer A, Wolfsberger S, et al. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg. 2015;122(4):803–811.
   PubMed Web of Science ®Google Scholar
• Micko A, Oberndorfer J, Weninger WJ, et al. Challenging Knosp high-grade pituitary adenomas. J Neurosurg. 2019;132(6):1739–1746.
   PubMed Web of Science ®Google Scholar
• Buchy M, Lapras V, Rabilloud M, et al. Predicting early post-operative remission in pituitary adenomas: evaluation of the modified Knosp classification. Pituitary. 2019;22(5):467–475.
   PubMed Web of Science ®Google Scholar